Jua Choi - Concepedia

Author

Jua Choi

Cedars-Sinai Medical Center ORCID

Also Known As

J Choi, J. Choi, J.-O. Choi, James J Driscoll, Jua Choi, TEAMMATE Trial Investigators

Publications

2.6K

Citations

H-Index

Concepts

All Affiliations

Cedars-Sinai Medical Center Translational Research in Oncology Inserm

About

Jua Choi is an author at Cedars-Sinai Medical Center specializing in immunotherapy, medicine, and autoimmune disease.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	132
2	Immunology	3	3	120
3	Nephrology	3	3	120
4	Autoimmune Disease	3	3	116
5	Allergy	1	1	12

Jua Choi

Publications

Citations

H-Index

Page 1

	Year	Citations
IgG Endopeptidase in Highly Sensitized Patients Undergoing Transplantation Stanley C. Jordan, Tomas Lorant, Jua Choi, New England Journal of Medicine	2017	350
Assessment of Tocilizumab (Anti–Interleukin-6 Receptor Monoclonal) as a Potential Treatment for Chronic Antibody-Mediated Rejection and Transplant Glomerulopathy in HLA-Sensitized Renal Allograft Recipients Jua Choi, O. Aubert, Ashley Vo, American Journal of Transplantation	2017	342
A Phase I/II Trial of the Interleukin-6 Receptor–Specific Humanized Monoclonal (Tocilizumab) + Intravenous Immunoglobulin in Difficult to Desensitize Patients Ashley Vo, Jua Choi, Irene Kim, Transplantation	2015	196
A Phase I/II Placebo-Controlled Trial of C1-Inhibitor for Prevention of Antibody-Mediated Rejection in HLA Sensitized Patients Ashley Vo, Adriana Zeevi, Jua Choi, Transplantation	2015	152
Benefits of Rituximab Combined With Intravenous Immunoglobulin for Desensitization in Kidney Transplant Recipients Ashley Vo, Jua Choi, Kristen Cisneros, Transplantation	2014	131
A phase I/II, double-blind, placebo-controlled study assessing safety and efficacy of C1 esterase inhibitor for prevention of delayed graft function in deceased donor kidney transplant recipients Stanley C. Jordan, Jua Choi, Olivier Aubert, American Journal of Transplantation	2018	97
Differences in pathologic features and graft outcomes in antibody-mediated rejection of renal allografts due to persistent/recurrent versus de novo donor-specific antibodies Mark Haas, James Mirocha, Nancy L. Reinsmoen, Kidney International Renal PathologyImmunologyImmunotherapyGraft OutcomesGraft Survival	2017	90
Factors Predicting Risk for Antibody-mediated Rejection and Graft Loss in Highly Human Leukocyte Antigen Sensitized Patients Transplanted After Desensitization Ashley Vo, Aditi Sinha, Mark Haas, Transplantation	2015	74
Impact of Tocilizumab (Anti–IL-6R) Treatment on Immunoglobulins and Anti-HLA Antibodies in Kidney Transplant Patients With Chronic Antibody-mediated Rejection Bongha Shin, Matthew J. Everly, Hao Zhang, Transplantation	2019	66
Three-Year Outcomes of a Randomized, Double-Blind, Placebo-Controlled Study Assessing Safety and Efficacy of C1 Esterase Inhibitor for Prevention of Delayed Graft Function in Deceased Donor Kidney Transplant Recipients Edmund Huang, Ashley Vo, Jua Choi, Clinical Journal of the American Society of Nephrology	2019	63

Page 1